Results 181 to 190 of about 139,449 (267)

Towards the clinical use of peripheral bile acids: Recommendations to limit their preanalytical and analytical sources of variability. [PDF]

Pract Lab Med
Joseph S, de Buyl S, Leclercq IA, Serafimov K, Feron O, Clerbaux LA.   +5 more
europepmc   +1 more source

Efeitos do ácido biliar tauroursodesoxicólico (TUDCA) na homeostase glicêmica = insulina e glucagon = Effects of the bile acid tauroursodeoxycholic (TUDCA) in glycemic homeostasis: insulin and glucagon

, 2017
Jean Franciesco Vettorazzi
openalex   +1 more source

Microencapsulation of Lactobacillus acidophilus LA-5 and Bifidobacterium animalis subsp. lactis BB-12 in alginate and pectin, and the effects on bacterial acid and bile resistance

Ayla Mumcu, Ayhan Temiz, Emir Baki Denkbaş   +2 more
openalex   +1 more source

Synthesis, Spectroscopic and Theoretical Studies of New Quaternary N,N-Dimethyl-3-phthalimidopropylammonium Conjugates of Sterols and Bile Acids [PDF]

, 2014
Bogumił Brycki, Hanna Koenig, Iwona Kowalczyk, Tomasz Pospieszny   +3 more
openalex   +1 more source

Population pharmacokinetics and dose–response relationships of mitoxantrone in children with acute myeloid leukaemia

British Journal of Clinical Pharmacology, EarlyView.
Background Information on mitoxantrone pharmacokinetics in children is lacking and reduced dosing regimens applied to infants are supported by limited scientific rationale. The current study characterized mitoxantrone pharmacokinetics in a childhood acute myeloid leukaemia patient population and provides a data‐informed assessment of dosing.
Andrew M. Brandon, Hinke Huisman‐Siebinga, Shelby Barnett, Paul Wetherell, Pamela Kearns, Brenda Gibson, Nicholas Heaney, Owen Smith, André Baruchel, Arnaud Petit, Andrew Moore, Kayode Ogungbenro, Alwin D. R. Huitema, Gareth J. Veal   +13 more
wiley   +1 more source

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta, Luigi Angelo Fiorito, Roberta Vescovo, Anna Virgilio, Giulia Amato, Giuseppe Cimino   +5 more
wiley   +1 more source

Circulating bile acids and HOMA-IR: cross-sectional results from the RoCAV population-based study. [PDF]

Front Endocrinol (Lausanne)
Grossi S, Giusti EM, Veronesi G, Delaiti S, Mancini A, Migliaccio L, Genova S, Costanzo S, Tuohy KM, Ferrario MM, Gianfagna F.   +10 more
europepmc   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source

Bile acids affect intestinal barrier function through FXR and TGR5. [PDF]

Front Med (Lausanne)
Song G, Xie Y, Yi L, Cheng W, Jia H, Shi W, Liu Q, Fang L, Xue S, Liu D, Zhu J, Zhao S.   +11 more
europepmc   +1 more source

Biliary secretion of alkalyne phosphatase (AP) in man: dependency on the bile acid (BA) secretion and detergency of BA pool

, 1983
Maurizio Ponz De Leon, Marco Bertolotti
openalex   +1 more source